Using an iterative approach to economic evaluation in the drug development process

Drug Development Research

Volumn 71, Issue 8, 2010, Pages 470-477

  Boyd, Kathleen Anne ^a   Fenwick, Elisabeth ^a   Briggs, Andrew ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

economic evaluation; health technology assessment; value of information

Indexed keywords

PLACEBO;

BAYES THEOREM; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MONITORING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECONOMIC EVALUATION; FUNDING; HEALTH CARE POLICY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS;

EID: 78651077016     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20421     Document Type: Review

References (29)

1. Ades A, Lu G, Claxton K,. 2003. Expected value of sample information in medical decision modeling. Med Decis Making 24: 207-227.
2. Briggs A,. 2000. Handling uncertainty in cost-effectiveness models. Pharmacoecon 17: 479-500.
3. Claxton K,. 1999a. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 8: 341-364.
4. Claxton K,. 1999b. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 8: 269-274.
5. Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S,. 2004. A pilot study of the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment Programme. Health Technol Assess 8: 1-118.
6. Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, et al. 2005. A pilot study of value of information analysis to support research recommendations for the National Institute for Health and Clinical Excellence, Centre for Health Economics Research paper 4. York, UK: University of York.
7. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M,. 2008. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 337: 979-983.
8. DiMasi J,. 2002. The value of improving the productivity of the drug development process: Faster times and better decisions. Pharmacoecon 20: 1-10.
9. DiMasi J, Hansen R, Grabowski H,. 2003. The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185.
10. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G,. 2005 Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press.
11. Drummond M, McGuire A, editors. 2001. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press.
12. Fenwick E, Sculpher M, Claxton K, Briggs A,. 1999. Improving the efficiency and relevance of health technology assessment: the role of decision analytic modelling, Health Economics Study Group discussion paper, Birmingham, UK.
13. Fenwick E, Palmer S, Claxton K, Sculpher M, Abrams K, Sutton A,. 2006. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery. Med Decis Making 26: 480-497.
14. Glick H, Polsky D, Schulman K,. 2001. Trial-based economic evaluations: an overview of design and analysis. In:, Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press. p 113-140.
15. Glick H, Doshi J, Sonnad S, Polsky D,. 2007. Economic evaluation in clinical trials. Oxford: Oxford University Press.
16. Hjelmgren J, Berggren F, Andersson F,. 2001. Health economic guidelines: similarities, differences and some implications. Val Health 4: 225-249.
17. Hoffmann-La Roche Ltd. 2010. Research and development value chain. Roche. Available online at: (cited 9 June 2010).
18. Janodia M, Sreedhar D, Ligade V, Pise A, Udupa N,. 2007. Drug development process: a review. Pharmainfo.net. Available online at: (cited 8 June 2010).
19. Kuntz K, Weinstein M,. 2001. Modelling in economic evaluation. In:, Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press. p 141-171.
20. Merck, Sharp and Dohme. Discovery and Development, Clinical Development. Merck Available online at: (cited 9 June 2010).
21. National Institute for Health and Clinical Excellence. 2008. Guide to methods of technology appraisal. UK: NICE. Available online at
22. National Institute for Health and Clinical Excellence. Scientific Advice Consultancy Service. Cited July 2010. Available online at
23. Pfizer Ltd. Overview of the clinical trials process. Pfizer. Available online at: Overview.aspx (cited 9 June 2010).
24. Sculpher M, Drummond M, Buxton M,. 1997. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res 2: 26-30.
25. Sculpher M, Claxton K, Drummond M, McCabe C,. 2006. Whither trial-based economic evaluation for health care decision making? Health Econ 15: 677-687.
26. Spiegelhalter D, Myles J, Jones D, Abrams K,. 1999. An introduction to Bayesian methods in health technology assessment. BMJ 319: 508-512.
27. Taylor R, Drummond M, Salkeld G, Sullivan D,. 2004. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329: 972-975.
28. Vallejo-Torres L, Steuten L, Buxton M,. 2008. Integrating health economics modelling in the product development cycle of medical devices: a Bayesian approach. Int J Technol Assess Health Care 24: 459-464.
29. Weinstein M, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce B,. 2003. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Val Health 6: 9-17.